Mr Shkreli made headlines in September when his firm hiked up prices of a drug used to treat those with weakened immune systems caused by illnesses like HIV by 5,000 per cent, raising costs from around $13.50 per pill to $750.
But now it seems his actions may have come back to haunt him. According to Business Insider, Turing Pharmaceuticals recorded a $14.6million net loss in the quarter which culminated at the end of September.
The net revenue of the drug in question, Darapim, as well as Vecamyl – a drug to treat high blood pressure, was $5.6million.
However, revenue since the end of September wasn't included in the latest figures.
Following the controversy, Mr Shkreli vowed to lower the price of Daraprim to a more affordable price which he claimed allowed the company to "make a profit - but a very small profit”.
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies